Literature DB >> 33112940

Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.

Helen T Chifotides1, Lucia Masarova1, Mansour Alfayez1, Naval Daver1, Yesid Alvarado1, Elias Jabbour1, Marina Konopleva1, Hagop M Kantarjian1, Keyur P Patel2, Courtney D DiNardo1, Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33112940      PMCID： PMC7656917          DOI： 10.1182/bloodadvances.2020001528

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  37 in total

1.  Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.

Authors:  Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

2.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

Authors:  Haefaa Alchalby; Tatjana Zabelina; Thomas Stübig; Anja van Biezen; Martin Bornhäuser; Paolo Di Bartolomeo; Dietrich Beelen; Jean Yves Cahn; Peter Dreger; William Schroyens; Theo de Witte; Eduardo Olavarria; Nicolaus Kröger
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-04       Impact factor: 5.742

Review 3.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

4.  A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Authors:  Prithviraj Bose; Srdan Verstovsek; Jorge E Cortes; Susan Tse; Yvonne Gasior; Nitin Jain; Elias J Jabbour; Zeev Estrov; Yesid Alvarado; Courtney D DiNardo; Naveen Pemmaraju; Steven M Kornblau; Tapan M Kadia; Naval G Daver; Kiran Naqvi; Nicholas J Short; Lucia Masarova; John Villareal; Sherry A Pierce; Graciela Nogueras-Gonzalez; Xuelin Huang; Guillermo Garcia-Manero; Hagop M Kantarjian; Farhad Ravandi
Journal:  Leukemia       Date:  2020-02-25       Impact factor: 11.528

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

6.  Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.

Authors:  Steven M Chan; Daniel Thomas; M Ryan Corces-Zimmerman; Seethu Xavy; Suchita Rastogi; Wan-Jen Hong; Feifei Zhao; Bruno C Medeiros; David A Tyvoll; Ravindra Majeti
Journal:  Nat Med       Date:  2015-01-19       Impact factor: 87.241

Review 7.  The role of IDH mutations in acute myeloid leukemia.

Authors:  Guillermo Montalban-Bravo; Courtney D DiNardo
Journal:  Future Oncol       Date:  2018-03-15       Impact factor: 3.674

8.  Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis.

Authors:  Mythri Mudireddy; Naseema Gangat; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-06-11       Impact factor: 11.037

9.  Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.

Authors:  Courtney D DiNardo; Anthony S Stein; Eytan M Stein; Amir T Fathi; Olga Frankfurt; Andre C Schuh; Hartmut Döhner; Giovanni Martinelli; Prapti A Patel; Emmanuel Raffoux; Peter Tan; Amer M Zeidan; Stéphane de Botton; Hagop M Kantarjian; Richard M Stone; Mark G Frattini; Frederik Lersch; Jing Gong; Diego A Gianolio; Vickie Zhang; Aleksandra Franovic; Bin Fan; Meredith Goldwasser; Scott Daigle; Sung Choe; Bin Wu; Thomas Winkler; Paresh Vyas
Journal:  J Clin Oncol       Date:  2020-10-29       Impact factor: 44.544

10.  Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.

Authors:  Eytan M Stein; Courtney D DiNardo; Amir T Fathi; Alice S Mims; Keith W Pratz; Michael R Savona; Anthony S Stein; Richard M Stone; Eric S Winer; Christopher S Seet; Hartmut Döhner; Daniel A Pollyea; James K McCloskey; Olatoyosi Odenike; Bob Löwenberg; Gert J Ossenkoppele; Prapti A Patel; Mikhail Roshal; Mark G Frattini; Frederik Lersch; Aleksandra Franovic; Salah Nabhan; Bin Fan; Sung Choe; Hongfang Wang; Bin Wu; Lei Hua; Caroline Almon; Michael Cooper; Hagop M Kantarjian; Martin S Tallman
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113
View more
  9 in total

Review 1.  Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.

Authors:  Lucia Masarova; Courtney D DiNardo; Prithviraj Bose; Naveen Pemmaraju; Naval G Daver; Tapan M Kadia; Helen T Chifotides; Lingsha Zhou; Gautam Borthakur; Zeev Estrov; Marina Konopleva; Srdan Verstovsek
Journal:  Blood Adv       Date:  2021-04-27

Review 2.  JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors:  Andrew T Kuykendall; Rami S Komrokji
Journal:  J Immunother Precis Oncol       Date:  2021-06-22

Review 3.  Accelerated Phase of Myeloproliferative Neoplasms.

Authors:  Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal:  Acta Haematol       Date:  2021-04-21       Impact factor: 2.195

Review 4.  Epigenetic Dysregulation of Myeloproliferative Neoplasms.

Authors:  Andrew Dunbar; Young Park; Ross Levine
Journal:  Hematol Oncol Clin North Am       Date:  2021-02-05       Impact factor: 3.722

Review 5.  Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease.

Authors:  Francesco Mannelli
Journal:  J Clin Med       Date:  2021-01-23       Impact factor: 4.241

Review 6.  Mitochondrial metabolism as a target for acute myeloid leukemia treatment.

Authors:  Svetlana B Panina; Jingqi Pei; Natalia V Kirienko
Journal:  Cancer Metab       Date:  2021-04-21

7.  Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.

Authors:  Sandra Castaño-Díez; Mónica López-Guerra; Cristina Bosch-Castañeda; Alex Bataller; Paola Charry; Daniel Esteban; Francesca Guijarro; Carlos Jiménez-Vicente; Carlos Castillo-Girón; Albert Cortes; Alexandra Martínez-Roca; Ana Triguero; José Ramón Álamo; Silvia Beà; Dolors Costa; Dolors Colomer; María Rozman; Jordi Esteve; Marina Díaz-Beyá
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

8.  Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.

Authors:  Sebastian Stasik; Clara Burkhard-Meier; Michael Kramer; Jan M Middeke; Uta Oelschlaegel; Katja Sockel; Gerhard Ehninger; Hubert Serve; Carsten Müller-Tidow; Claudia D Baldus; Christoph Röllig; Martin Bornhäuser; Uwe Platzbecker; Christian Thiede
Journal:  Blood Adv       Date:  2022-06-14

Review 9.  Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence.

Authors:  Galia Stemer; Jacob M Rowe; Yishai Ofran
Journal:  Blood Lymphat Cancer       Date:  2021-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.